1-3 of 3
Emily Dunkelberger
Close
Sort by
Journal Articles

Long-Term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study

Anna Conrey, Ingrid Frey, Nancy Asomaning, Ruth Pierre Charles, Dina Parekh, Julia Xu, Kang Le, Britney Kruah, Quan Li, Emily Dunkelberger, Troy Cellmer, Amber M Yates, Megan Wind-Rotolo, Neal Jeffries, William A Eaton, Swee Lay Thein
Journal: Blood
Blood (2023) 142 (Supplement 1): 273.
https://doi.org/10.1182/blood-2023-180165
Published: 2023
Journal Articles

Functional and Multi-Omics Signatures of Mitapivat Efficacy upon Activation of Pyruvate Kinase in Red Blood Cells from Patients with Sickle Cell Disease

Angelo D'Alessandro, Kang Le, Maureen Lundt, Quan Li, Emily Dunkelberger, Troy Cellmer, Andrew J Worth, Spurthi Patil, Chris Huston, Abby Grier, Monika monikA.dzieciatkow, Daniel Stephenson, William A Eaton, Swee Lay Thein
Journal: Blood
Blood (2023) 142 (Supplement 1): 2485.
https://doi.org/10.1182/blood-2023-181213
Published: 2023
Journal Articles

Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Julia Z. Xu, MDMS, Anna Conrey, NP, Ingrid Frey, RN, BSN, MS, James Nichols, RN, Laurel A Menapace, MD, Laxminath Tumburu, PhD, Timothy Lequang, MSc, Quan Li, PhD, Emily Dunkelberger, PhD, Eric Henry, PhD, Troy Cellmer, PhD, Varsha Iyer, Heidi Mangus, BS, Charles Kung, PhD, Lenny Dang, PhD, Penelope A. Kosinski, MS, Peter Hawkins, PhD, Neal Jeffries, PhD, William Eaton, MD, Swee Lay Thein, DSc, FRCP, MBBS, MRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-137716
Published: 2020